To Assess Allisartan Isoproxil/Sustained-Release Indapamide in Patients With Essential Hypertension Uncontrolled With Allisartan Isoproxil

Clinical trial NCT06500689 · COMPLETED

Trial details

NCT number: NCT06500689
Sponsor: Shenzhen Salubris Pharmaceuticals Co., Ltd.
Status: COMPLETED
Phase: Phase 3
Study type: INTERVENTIONAL

Essential Hypertension

Start date: 2021-12-30
Primary completion: 2023-11-27
Enrollment: 366

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.